Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults (Q33910062)

30 July 2017

1 reference

title

Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults (English)

1 reference

30 July 2017

1 reference

9

A Walker

1 reference

30 July 2017

8

T Peto

1 reference

30 July 2017

J Darbyshire

1

1 reference

30 July 2017

M Foulkes

2

1 reference

30 July 2017

R Peto

3

1 reference

30 July 2017

W Duncan

4

1 reference

30 July 2017

A Babiker

5

1 reference

30 July 2017

R Collins

6

1 reference

30 July 2017

M Hughes

7

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

2000

0 references

published in

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

3

0 references

page(s)

CD002039

1 reference

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

A controlled trial of zidovudine in primary human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

Antiretroviral treatment in 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002039

10.1002/14651858.CD002039

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference